Skip to main content

Table 2 The Symptoms Recurrence rate after one month of discontinuation of the treatment Protocol and relation to demographic characteristic

From: Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin

 

Symptoms Recurrence

P value

No

N = 48

Yes

N = 12

Treatment Protocol; n (%)

 Group I; n = 30

20 (66.7)

10 (33.3)

0.001*

 Group II; n = 30

28 (93.3)

2 (6.7)

Age; (years)

 qMean ± SD

40.04 ± 17.4

61.67 ± 12.1

0.001*

 95% CI1 for Mean

  Lower bound

35.00

54.00

 

  Upper bound

45.08

69.32

 

  Range (Max–Min)

65.00 (75–10)

35.00 (77–42)

 

Gender; n (%)

 Male; n = 21

18 (85.7)

3 (14.3)

0.325a

 Female; n = 39

30 (76.9)

9 (23.1)

 
  1. 195% Confidence Interval of Mean
  2. *P value ≤ 0.05 is considered significant by (independent sample t test)
  3. aP value > 0.05 is considered non-significant by (Chi-square test)